

CLEAN VERSION OF REWRITTEN, ADDED, AND/OR CANCELLED
CLAIMS PURSUANT TO 37 C.F.R. §1.121 (c)(1)(i)

1-5. Cancelled.

6. (Previously presented) A method of elevating white blood cell count in a mammal comprising:

- a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and
- b) administering said CLA composition to said mammal under conditions such that the white blood cell count of the mammal is elevated.

7. (Previously presented) The method of Claim 6, wherein said white blood cells are selected from the group consisting of B cells, T cells and Natural Killer cells.

8. (Previously presented) The method of Claim 6, wherein said CLA composition is administered orally.

9. (Previously presented) The method of Claim 6, wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid

10. (Previously presented) The method of Claim 6, wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

11. (Previously presented) The method of Claim 6, wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

12. (Previously presented) A method of treating type I or IgE mediated hypersensitivity in a mammal comprising:

- a) providing a CLA composition comprising t10,c12 octadecadienoic acid and c9,t11

octadecadienoic acid in a ratio of about 1.2:1 to 3:1 and a mammal; and

b) administering said CLA composition to said mammal under conditions such that said type I or IgE mediated hypersensitivity is reduced.

13. (Canceled).

14. (Previously presented) The method of Claim 7, wherein said CLA composition is administered orally.

15. (Previously presented) The method of Claim 7, wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid

16. (Previously presented) The method of Claim 7 wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

17. (Previously presented) The method of Claim 7, wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.